Intrommune Therapeutics, Inc. — Form D
Intrommune Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2024-01-22. The offering totals $10.0M, of which $210K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-01-22
- Form: D
- Accession: 0001104659-24-005583
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $210K
- Remaining: $9.8M
- Minimum investment: $1K
- Investors: 7
- Date of first sale: 2023-12-06
- Security types: debt
- Revenue range: No Revenues
- SEC file number: 021-503083
Issuer
- Name: Intrommune Therapeutics, Inc.
- CIK: 0001736977
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 20 W 125TH ST. UNIT #1, NEW YORK, NY, 10027
- Phone: 6464948432
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Erick Berglund | Director | NEW YORK, NY |
| Michael Nelson | Director | Davidson, NC |
| Hemanshu Pandya | Director | NEW YORK, NY |
| William Reisacher | Director | NEW YORK, NY |
| Jonathan Rich | Director | NEW YORK, NY |
| Michael Nelson | Executive Officer | Davidson, NC |
| Michael Nelson | Promoter | Davidson, NC |
| Erick Berglund | Promoter | NEW YORK, NY |
| Anthony Robinson | Promoter | Ontario, CA |
| Nelson Michael | Director | New York, NY |
| Nelson Michael | Executive Officer | New York, NY |
Other filings by this issuer (4)
More